. 2010 Aug 13;118(11):1557–1563. doi: 10.1289/ehp.1001928

Table 1.

Body and liver weights and concentrations of urinary TRI metabolites, transaminase, and plasma and hepatic TG in mPPARα, Pparα-null, and hPPARα mice after TRI exposure.

Mouse genotype	n	TRI (ppm)	Weight (g)		Liver/body weight ratio	TRI metabolites		Transaminase		TG
Mouse genotype	n	TRI (ppm)	Body	Liver	Liver/body weight ratio	TCE (mg)	TCA (mg)	AST (IU/L)	ALT (IU/L)	Plasma (mg/dL)	Liver (mg/g)
mPPARα	6	0	25.1 ± 0.7	1.17 ± 0.04	4.68 ± 0.17	ND	ND	19.9 ± 1.3	6.1 ± 0.8	70.4 ± 17.7	25.7 ± 5.1
	6	1,000	25.0 ± 2.3	1.62 ± 0.15^#	6.47 ± 0.16^#	4.8 ± 3.7	0.49 ± 0.39^##	30.4 ± 3.6^#	8.6 ± 1.8^#	66.7 ± 22.8	31.3 ± 4.3
	6	2,000	26.1 ± 1.3	1.74 ± 0.11^#	6.67 ± 0.48^#	6.2 ± 2.0	0.49 ± 0.14^##	32.4 ± 10.1^#	9.2 ± 1.0^#	86.0 ± 25.0	33.7 ± 8.5
Pparα-null	5	0	23.6 ± 1.5	1.22 ± 0.09	5.19 ± 0.31^*	ND	ND	18.4 ± 1.0	6.0 ± 1.4	77.3 ± 12.7	35.0 ± 2.7^*
	5	1,000	22.8 ± 0.7	1.47 ± 0.14^#	6.43 ± 0.44^#	7.5 ± 1.1	0.26 ± 0.09^##	26.3 ± 3.1^#	9.1 ± 0.9^#	116.4 ± 24.7	51.2 ± 6.9
	5	2,000	23.6 ± 1.8	1.67 ± 0.15^#	7.05 ± 0.14^#,^†	6.4 ± 4.1	0.28 ± 0.17^##	32.9 ± 6.6^#	10.5 ± 1.3^#	102.5 ± 32.4	74.7 ± 22.0^#
hPPARα	6	0	21.6 ± 0.7^,^*	1.09 ± 0.06^**	5.04 ± 0.29	ND	ND	21.0 ± 1.8	5.6 ± 1.0	107.0 ± 30.7^*	45.6 ± 13.4^,^*
	6	1,000	21.9 ± 2.0	1.40 ± 0.16^#	6.39 ± 0.22^#	5.7 ± 2.4	0.53 ± 0.17	26.6 ± 5.3^#	8.1 ± 1.2^#	81.1 ± 17.1	72.2 ± 14.4^#
	6	2,000	20.9 ± 1.4	1.44 ± 0.25^#	6.98 ± 0.87^#	5.0 ± 1.9	0.43 ± 0.21	32.0 ± 5.6^#	9.0 ± 2.0^#	82.3 ± 35.0	85.4 ± 14.0^#

p < 0.05 compared with the mPPARα control group.

^**

p < 0.05 compared with the Pparα-null control group.

p < 0.05 compared with the the control group of the same genotype.

^##

p < 0.05 compared with the same treatment between genotypes.

^†

p < 0.05 between the 1,000 and 2,000 ppm TRI doses.

ND, not detected. Values are mean ± SD. TRI 0 ppm is the control.